In this Phase II clinical trial the investigators will use four human non-small cell lung
cancer cell lines that have been previously established in tissue culture laboratory. The
investigators will gene modify these tumor cells in the laboratory to block their TGF-beta
secretion. The investigators will inject the genetically engineered cells as vaccines in
patients with stages II to IV non-small cell lung cancer. Our rationale for using other
people's tumor cells is that lung tumor cell lines belonging to different people have been
shown to share common characteristics that are recognized by non-self immune systems.